The PD-1/PD-Ls pathway and autoimmune diseases

被引:373
作者
Dai, Suya [1 ]
Jia, Ru [1 ]
Zhang, Xiao [1 ]
Fang, Qiwen [1 ]
Huang, Lijuan [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Lab Med, Harbin 150086, Peoples R China
关键词
The PD-1/PD-Ls pathway; Soluble co-stimulatory molecule; Type 1 diabetes mellitus; Systemic lupus erythematosus; Rheumatoid arthritis; SYSTEMIC-LUPUS-ERYTHEMATOSUS; T-CELL-ACTIVATION; DEATH-1; PD-1; PATHWAY; PROGRAMMED DEATH-1; SOLUBLE PD-1; IN-VIVO; ANTITUMOR IMMUNITY; NOD MICE; METASTATIC MELANOMA; ABERRANT REGULATION;
D O I
10.1016/j.cellimm.2014.05.006
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The programmed death (PD)-1/PD-1 ligands (PD-Ls) pathway, is a new member of the B7/CD28 family, and consists of the PD-1 receptor and its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273). Recently, it is reported that PD-1, PD-L1 and PD-L2 also have soluble forms aside from their membrane bound forms. The soluble forms increase the diversity and complexity of PD-1/PD-Ls pathway in both composition and function. The PD-1/PD-Ls pathway is broadly expressed and exerts a wider range of immunoregulatory roles in T-cell activation and tolerance compared with other B7/CD28 family members. Studies show that the PD-1/PD-Ls pathway regulates the induction and maintenance of peripheral tolerance and protects tissues from autoimmune attack in physiological conditions. In addition, it is also involved in various diseases mediated by T cells, such as autoimmunity, tumor immunity, chronic viral infections, and transplantation immunity. In this review, we will summarize the relevance of the soluble forms and the latest researches on the role of PD-1/PD-Ls pathway in autoimmune diseases. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:72 / 79
页数:8
相关论文
共 50 条
[41]   The therapeutic potential of PD-1/PD-L1 pathway on immune-related diseases: Based on the innate and adaptive immune components [J].
Zhang, Peng ;
Wang, Yuting ;
Miao, Qianru ;
Chen, Ying .
BIOMEDICINE & PHARMACOTHERAPY, 2023, 167
[42]   The association between PD-1 gene polymorphisms and susceptibility to multiple sclerosis [J].
Hassani, Nasrin ;
Salmaninejad, Arash ;
Aslani, Saeed ;
Kamali-sarvestani, Eskandar ;
Vessal, Mahmood .
IMMUNOLOGICAL MEDICINE, 2023, 46 (02) :69-76
[43]   The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck [J].
Zandberg, Dan P. ;
Strome, Scott E. .
ORAL ONCOLOGY, 2014, 50 (07) :627-632
[44]   Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy [J].
Liu, Ning ;
Zhang, Renshuai ;
Shi, Qiang ;
Jiang, Hongfei ;
Zhou, Qihui .
BIOORGANIC CHEMISTRY, 2023, 136
[45]   The PD-1 Interactome [J].
Wang, Qi ;
Bardhan, Kankana ;
Boussiotis, Vassiliki A. ;
Patsoukis, Nikolaos .
ADVANCED BIOLOGY, 2021, 5 (09)
[46]   Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway [J].
Tremblay-LeMay, Rosemarie ;
Rastgoo, Nasrin ;
Chang, Hong .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[47]   Divergent Expression of PD-1 as Challenges and Chances of Immunotherapy Targeting PD-1 or PD-L1 in Cancer [J].
Huang, Haozhe .
BIOINFORMATICS AND BIOMEDICAL ENGINEERING, PT II, IWBBIO 2024, 2024, 14849 :55-69
[48]   Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus [J].
Bertsias, G. ;
Raptopoulou, A. ;
Coutala, E. ;
Mamoulaki, M. ;
Kritikos, H. ;
Sidiropoulos, P. ;
Boumpas, D. T. .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) :S55-S55
[49]   Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus [J].
G Bertsias ;
A Raptopoulou ;
E Coutala ;
M Mamoulaki ;
H Kritikos ;
P Sidiropoulos ;
DT Boumpas .
Arthritis Research & Therapy, 7
[50]   Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies [J].
Collins, M. ;
Michot, J. M. ;
Danlos, F. X. ;
Mussini, C. ;
Soularue, E. ;
Mateus, C. ;
Loirat, D. ;
Buisson, A. ;
Rosa, I. ;
Lambotte, O. ;
Laghouati, S. ;
Chaput, N. ;
Coutzac, C. ;
Voisin, A. L. ;
Soria, J. C. ;
Marabelle, A. ;
Champiat, S. ;
Robert, C. ;
Carbonnel, F. .
ANNALS OF ONCOLOGY, 2017, 28 (11) :2860-2865